£10 million approved for Liverpool LSTM’s AI Level 3 labs suite

The high containment Level 3 labs will handle pathogens for the acceleration, development and validation of new treatments that can be applied worldwide.

Containment Level 3 labs played a key role in the Covid-19 response, with Liverpool already hosting the largest number within the north west of England.

The new labs, supported by the Infection Innovation Consortium (iiCON), are scheduled to open in early 2027 and forecast to generate £40 million in investment in their first three years.

The project is part of the decade-long Liverpool City Region Life Sciences Innovation Zone programme which is predicted to attract up to £800 millions in public and private investment and create 8,000 new skilled jobs to the area.

“This investment strengthens Liverpool City Region’s position as a global hub for infection innovation and reinforces our commitment to fostering impactful collaborations, supporting SMEs, and creating high-value jobs,” said iiCON founding director professor Janet Hemingway. 

“Through iiCON’s specialist research platforms and translational expertise, we will work closely with partners to unlock the full potential of this facility, ensuring it delivers real-world impact for patients, communities, and the wider economy."

Pic: Shutterstock